← Leaderboards
Olivera J Finn
University Of Pittsburgh At Pittsburgh
$21,318,142
Attributed
$21,318,142
Total exposure
13
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.6M · FY2005–22$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$32,075,111 · 14
By mechanism
P01$13,093,682 · 4
R35$6,042,886 · 1
T32$5,402,199 · 1
R01$5,332,531 · 2
P50$1,483,862 · 2
P30$500,808 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Roy A Mariuzza$20,943,458
- Dario Aa Vignali$40,087,127
- Theresa L. Whiteside$29,550,469
- Charles R Rinaldo$100,535,685
- Peter X Wipf$9,740,940
Others in their field
Top investigators on “Tumor Antigens”
- William R Green · Dartmouth College$32,738,211
- John H Sampson · Duke University$30,849,602
- Catherine Ju-Ying Wu · Broad Institute, Inc.$30,485,072
- Elizabeth Marion Jaffee · Johns Hopkins University$26,862,085
- Ian M Thompson · University Of Texas Hlth Sci Ctr San Ant$24,066,354
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$20,250,477
Research focus
Tumor AntigensDendritic CellsBaseTumorVaccinesMolecularCancer VaccinesPreventionT-LymphocyteAntigensCytokineGlycopeptidesPeptidesMalignant NeoplasmsResponseClinical TrialsCellsLearningGrantImmune SystemNeoplasm /Cancer ImmunotherapyAnimal ModelImmunityMucins
Grant awards (79)
Immunoprevention and immunosurveillance of human non-viral cancers$786,933
R35 · FY2022 · CA · contact PI
Immunoprevention and immunosurveillance of human non-viral cancers$821,873
R35 · FY2021 · CA · contact PI
Immunoprevention and immunosurveillance of human non-viral cancers$880,514
R35 · FY2020 · CA · contact PI
Immunoprevention and immunosurveillance of human non-viral cancers$870,445
R35 · FY2019 · CA · contact PI
Immunoprevention and immunosurveillance of human non-viral cancers$819,666
R35 · FY2018 · CA · contact PI
Immunoprevention and immunosurveillance of human non-viral cancers$922,006
R35 · FY2017 · CA · contact PI
Immunoprevention and immunosurveillance of human non-viral cancers$941,449
R35 · FY2016 · CA · contact PI
Dendritic Cell Biology and Therapy$396,430
R01 · FY2015 · CA · contact PI
Dendritic Cell Biology and Therapy$385,909
R01 · FY2014 · CA · contact PI
Training in Cellular & Molecular Mechanisms of Tumor Rejection$455,434
T32 · FY2013 · CA · contact PI
Dendritic Cell Biology and Therapy$375,328
R01 · FY2013 · CA · contact PI
T Cell Immunity to Epithelial Tumor Mucins$257,218
R01 · FY2013 · CA · contact PI
Training in Cellular & Molecular Mechanisms of Tumor Rejection$455,540
T32 · FY2012 · CA · contact PI
Dendritic Cell Biology and Therapy$400,760
R01 · FY2012 · CA · contact PI
T Cell Immunity to Epithelial Tumor Mucins$312,611
R01 · FY2012 · CA · contact PI
T Cell Immunity to Epithelial Tumor Mucins$57,017
R01 · FY2012 · CA · contact PI
Training in Cellular & Molecular Mechanisms of Tumor Rejection$462,505
T32 · FY2011 · CA · contact PI
Dendritic Cell Biology and Therapy$402,260
R01 · FY2011 · CA · contact PI
T Cell Immunity to Epithelial Tumor Mucins$312,611
R01 · FY2011 · CA · contact PI
T Cell Immunity to Epithelial Tumor Mucins$22,036
R01 · FY2011 · CA · contact PI
Training in Cellular & Molecular Mechanisms of Tumor Rejection$413,502
T32 · FY2010 · CA · contact PI
T Cell Immunity to Epithelial Tumor Mucins$322,280
R01 · FY2010 · CA · contact PI
P2 - CYCLIN B1 IN IMMUNOTHERAPY, DIAGNOSIS, AND PROGNOSIS OF LUNG CANCER$318,563
P50 · FY2010 · CA · contact PI
T Cell Immunity to Epithelial Tumor Mucins$37,875
R01 · FY2010 · CA · contact PI
Dendritic Cell Biology and Therapy$520,000
P01 · FY2009 · CA · contact PI
Training in Cellular & Molecular Mechanisms of Tumor Rejection$365,947
T32 · FY2009 · CA · contact PI
T Cell Immunity to Epithelial Tumor Mucins$322,280
R01 · FY2009 · CA · contact PI
P2 - CYCLIN B1 IN IMMUNOTHERAPY, DIAGNOSIS, AND PROGNOSIS OF LUNG CANCER$318,569
P50 · FY2009 · CA · contact PI
Dendritic Cell Biology and Therapy$1,332,338
P01 · FY2008 · CA · contact PI
Training/Cellular/Molecular Mechanisms/Tumor Rejection$366,074
T32 · FY2008 · CA · contact PI
Evaluation of Cancer Vaccines Based on MUC1processed by dendritic cells$356,221
P01 · FY2008 · CA · contact PI
CYCLIN B1 IN IMMUNOTHERAPY, DIAGNOSIS, AND PROGNOSIS OF LUNG CANCER$319,325
P50 · FY2008 · CA · contact PI
Dendritic Cell Biology and Therapy$1,337,018
P01 · FY2007 · CA · contact PI
Training/Cellular/Molecular Mechanisms/Tumor Rejection$403,982
T32 · FY2007 · CA · contact PI
Evaluation of Cancer Vaccines Based on MUC1processed by dendritic cells$357,749
P01 · FY2007 · CA · contact PI
CYCLIN B1 IN IMMUNOTHERAPY, DIAGNOSIS, AND PROGNOSIS OF LUNG CANCER$322,405
P50 · FY2007 · CA · contact PI
Dendritic Cell Biology and Therapy$1,341,490
P01 · FY2006 · CA · contact PI
Training/Cellular/Molecular Mechanisms/Tumor Rejection$385,006
T32 · FY2006 · CA · contact PI
T Cell Immunity to Epithelial Tumor Mucins$285,691
R01 · FY2006 · CA · contact PI
EVALUATION OF CANCER VACCINES BASED ON GLYCOPEPTIDES /DC$224,619
P01 · FY2006 · CA · contact PI
CYCLIN B1 IN IMMUNOTHERAPY, DIAGNOSIS, AND PROGNOSIS OF LUNG CANCER$205,000
P50 · FY2006 · CA · contact PI
Cyclin B-1 As a Tumor-specific Antigen in Oral Carcinoma$145,720
P01 · FY2006 · DE · contact PI
Dendritic Cell Biology and Therapy$1,337,725
P01 · FY2005 · CA
Training/Cellular/Molecular Mechanisms/Tumor Rejection$390,340
T32 · FY2005 · CA
T Cell Immunity to Epithelial Tumor Mucins$293,193
R01 · FY2005 · CA
EVALUATION OF CANCER VACCINES BASED ON GLYCOPEPTIDES /DC$218,717
P01 · FY2005 · CA
Cyclin B-1 As a Tumor-specific Antigen in Oral Carcinoma$141,475
P01 · FY2005 · DE
Dendritic Cell Biology and Therapy$1,300,247
P01 · FY2004 · CA
Training/Cellular/Molecular Mechanisms/Tumor Rejection$356,042
T32 · FY2004 · CA
T Cell Immunity to Epithelial Tumor Mucins$293,802
R01 · FY2004 · CA
EVALUATION OF CANCER VACCINES BASED ON GLYCOPEPTIDES /DC$212,819
P01 · FY2004 · CA
Cyclin B-1 As a Tumor-specific Antigen in Oral Carcinoma$137,354
P01 · FY2004 · DE
ADMINISTRATIVE CORE$82,113
P01 · FY2004 · CA
TRAINING IN CELL &MOLECU MECHANISMS OF TUMOR REJECTION$386,687
T32 · FY2003 · CA
DENDRITIC CELL BIOLOGY AND THERAPY$380,000
P01 · FY2003 · CA
T Cell Immunity to Epithelial Tumor Mucins$295,247
R01 · FY2003 · CA
Cyclin B-1 As a Tumor-specific Antigen in Oral Carcinoma$133,353
P01 · FY2003 · DE
DENDRITIC CELL BIOLOGY AND THERAPY$1,625,253
P01 · FY2002 · CA
TRAINING IN CELL &MOLECU MECHANISMS OF TUMOR REJECTION$346,581
T32 · FY2002 · CA
T Cell Immunity to Epithelial Tumor Mucins$296,687
R01 · FY2002 · CA
Immunology program$250,404
P30 · FY2002 · CA
DENDRITIC CELL BASED CANCER VACCINES$209,143
P51 · FY2002 · RR
Cyclin B-1 As a Tumor-specific Antigen in Oral Carcinoma$129,469
P01 · FY2002 · DE
BREAST TUMOR SPECIFIC IMMUNITY VACCINE DESIGN$0
P41 · FY2002 · RR
DENDRITIC CELLS--A NEW TUMOR ANTIGEN DISCOVERY SYSTEM$0
P01 · FY2002 · CA
CYCLIN B1 AS A NONSMALL LUNG TUMOR ANTIGEN$0
P50 · FY2002 · CA
BREAST TUMOR SPECIFIC IMMUNITY VACCINE DESIGN$0
P41 · FY2002 · RR
DENDRITIC CELL BIOLOGY AND THERAPY$1,582,898
P01 · FY2001 · CA
TRAINING IN CELL &MOLECU MECHANISMS OF TUMOR REJECTION$355,075
T32 · FY2001 · CA
Immunology program$250,404
P30 · FY2001 · CA
CYCLIN B1 AS A NONSMALL LUNG TUMOR ANTIGEN$0
P50 · FY2001 · CA
BREAST TUMOR SPECIFIC IMMUNITY VACCINE DESIGN$0
P41 · FY2001 · RR
Immunology program$0
P30 · FY2001 · CA
DENDRITIC CELLS--A NEW TUMOR ANTIGEN DISCOVERY SYSTEM$0
P01 · FY2001 · CA
T CELL IMMUNITY TO EPITHELIAL TUMOR MUCINS$263,296
R01 · FY2000 · CA
TRAINING IN CELL &MOLECU MECHANISMS OF TUMOR REJECTION$259,484
T32 · FY2000 · CA
DENDRITIC CELLS--A NEW TUMOR ANTIGEN DISCOVERY SYSTEM$197,104
P01 · FY2000 · CA
CONFERENCE--CELLULAR IMMUNITY &IMMUNOTHERAPY OF CANCER$10,000
R13 · FY2000 · CA
Immunology program$0
P30 · FY2000 · CA